Ubivac files Form D for equity offering, discloses $80,000 raised so far
The Portland, Oregon biotechnology company reported two investors in an ongoing offering under Rule 506(b) exemption.
Ubivac, Inc., a Delaware corporation based in Portland, Oregon, filed a Form D notice with the Securities and Exchange Commission disclosing a new securities offering. The filing lists a date of first sale of 2026-08-02.1
The company claimed exemption under Rule 506(b) of Regulation D.1 The securities offered include equity as well as an option, warrant or other right to acquire another security.1
Ubivac reported total amount sold of $80,000, with the total offering amount and remaining amount to be sold both listed as indefinite.1 The company reported a total of 2 investors who have already invested in the offering.1 The minimum investment accepted from any outside investor was set at $10,000.1
The filing reported $0 in sales commissions and $0 in finders' fees.1 Proceeds to date allocated for payments to executive officers, directors or promoters were listed as $0, estimated, with a note that proceeds may be used to pay normal executive compensation in an amount not yet estimable.1
The filing names several related persons at the company's Boones Ferry Road address in Portland. Bernard Fox, Ph.D. is listed as an executive officer and director.1 Hong-Ming Hu, Ph.D. is also listed as an executive officer and director.1 Bernard A. Fox, III is listed as an executive officer.1 Sung Poblete, R.N., Ph.D. is listed as a director.1
The company identified its industry group as biotechnology within health care.1 Ubivac declined to disclose its revenue range or aggregate net asset value range.1 The company indicated it does not intend the offering to last more than one year.1
The Form D was signed by Bernard A. Fox, Ph.D., President and CEO, on 2026-08-25.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.